Acadia Pharmaceuticals (ACAD) PT Lowered to $24 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $21.47 --0%
Rating Summary:
16 Buy, 11 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Rating Summary:
16 Buy, 11 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Join SI Premium – FREE
BMO Capital analyst Evan David Seigerman lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $24.00 (from $31.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Acadia Pharma (ACAD) Tops Q3 EPS by 11c, Beats on Revenue; Offers FY26 Revenue Guidance
- Insulet Corporation (PODD) PT Raised to $171 at UBS
- Performance Food Group (PFGC) PT Raised to $133 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
